P. Mohr, Czech Republic

National Institute of Mental Health Clinical Dept.
Graduated from the Medical Faculty, Charles University Prague in 1990; in 2001 obtained his Ph.D. in Neurosciences. Prof. Mohr works since 1991 at the National Institute of Mental Health, Czechia (formerly the Prague Psychiatric Center), currently as the Clinical Director. From 1995 to 1998, he was a visiting scientist at the Nathan Kline Institute for Psychiatric Research in Orangeburg, New York. Dr. Mohr is a Professor of Psychiatry at the 3rd Medical Faculty, Charles University, teaching pre-graduate medical students and postgraduate students in the PhD program of Neurosciences. He serves as an editorial board member of several international and national psychiatric journals, member of the EPA, President of the Czech Psychiatric Association (2019-2022), Board Member of the Czech Neuropsychopharmacological Society (President 2009-2011), President of the Czech Brain Council (since 2011). Main research interest is clinical neurosciences; Prof. Mohr authored numerous scientific papers in peer-reviewed journals, both in Czech and English, chapters in textbooks and monographs, received several awards (including Czech National Psychiatric Award 2018).

Presenter of 4 Presentations

Workshop: Medication Deprescribing in Elderly Patients with Mental Disorders: Why, When, and How? (ID 273) No Topic Needed

Live Q&A

Session Icon
Pre-Recorded with Live Q&A, Section
Date
Tue, 13.04.2021
Session Time
10:00 - 11:30
Room
Channel 6
Lecture Time
11:08 - 11:28
LIVE - NPA Symposium: COVID-19 Pandemic and Psychiatry in Europe: Challenges, Experiences and Future Perspectives from Different European Countries (ID 346) No Topic Needed
LIVE - NPA Symposium: COVID-19 Pandemic and Psychiatry in Europe: Challenges, Experiences and Future Perspectives from Different European Countries (ID 346) No Topic Needed

NPA0004 - Experiences and Projections for the Future of Research, Training and Other Academic Activities: Will It Be the Same?

Session Icon
Live
Date
Tue, 13.04.2021
Session Time
08:00 - 09:30
Room
Channel 1
Lecture Time
08:51 - 09:08

ABSTRACT

Abstract Body

The global SARS-CoV-2 pandemic with subsequently imposed restrictions and lockdowns also radically disrupted academic life. Many research projects involving recruitment of human subjects were abruptly put on hold, educational activities have moved into online trainings, scientific meetings have been transformed into virtual events. Social distancing does not restrict only everyday human contact but also limits direct exchange of clinical, educational, and research experiences, professional and academic networking, sharing ideas. Besides all the drawbacks, does the current situation also bring any advantages? Every challenge results in new opportunities. Although the online congresses will most likely never fully replace real-life experience, it was found that many work meetings can be held more efficiently via online communication. Saving time, cutting costs of travel and accommodation, plus other expenses, may help to allocate limited resources where needed. Similarly, while practical medical education and training cannot be substituted for remote broadcasting, many theoretical presentations can. More importantly, epidemic of COVID-19 is a unique opportunity for mental health research, to study individual and population consequences of the virus, its impact on psychiatric patients. It is still early to predict whether and when research, training, meetings, and other academic activities return back to “normal”, but appears that some changes are here to stay.

Hide
Workshop: Medication Deprescribing in Elderly Patients with Mental Disorders: Why, When, and How? (ID 273) No Topic Needed

W0063 - Antipsychotics for Elderly with Psychosis: Deprescribe or Continue?

Session Icon
Pre-Recorded with Live Q&A, Section
Date
Tue, 13.04.2021
Session Time
10:00 - 11:30
Room
Channel 6
Lecture Time
10:51 - 11:08

ABSTRACT

Abstract Body

Maintenance treatment with antipsychotics remains the key principle in the long-term management of psychotic disorders. For some patients, it means life-long use of medication. Continuous drug administration helps to prevent relapses, maintain remission, and achieve functional recovery. Moreover, epidemiological data suggest that antipsychotic treatment significantly reduces mortality rates of schizophrenia patients. On the other hand, some authors argue that antipsychotic drugs may lose its efficacy over time, their long-term exposure results in more harm than benefit. Especially elderly patients are more sensitive to side effects. Several studies which followed-up patient cohorts over the span of several decades found that there are schizophrenia patients who can achieve good functional outcome and full recovery without antipsychotic treatment. Therefore, it is paramount to identify those individuals, particularly among elderly psychotic patients, who can thrive and benefit from timely antipsychotic discontinuation.

Hide